Maxygen, Inc. (Redwood City, CA), has announced the licensing of its proprietary dengue virus antigen technology to Sanofi Pasteur (Lyon, France).
Maxygen, Inc. (Redwood City, CA), has announced the licensing of its proprietary dengue virus antigen technology to Sanofi Pasteur (Lyon, France). Under the terms of the agreement, Maxygen will transfer to Sanofi Pasteur a portfolio of preclinical dengue antigens for development and worldwide commercialization of a second-generation vaccine. The deal could be worth up to $24.5 million for Maxygen. Sanofi Pasteur had recently presented positive results for their tetravalent dengue vaccine candidate after Phase 2 trials using Acambis technology.
The dengue virus is a mosquito-borne pathogen that infects over 50 million people each year, causing 500,000 hospitalizations, according to the World Health Organization.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
INTERPHEX 2025: Critical Role of Walk-In Chambers in Bio/Pharma Development and Manufacturing
April 3rd 2025Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, sat down with the PharmTech Group at INTERPHEX 2025 to discuss the design and critical role of walk-in chambers in the bio/pharmaceutical industry.